Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 3
2013 6
2014 3
2015 4
2016 3
2017 1
2018 2
2019 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Myelodysplastic syndrome associated with isolated del(5q)"
Page 1
Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients.
Azevedo RS, Belli C, Bassolli L, Ferri L, Perusini MA, Enrico A, Pereira T, Junior W, Buccheri V, Pinheiro RF, Magalhaes SM, Schuster S, Castelli JB, Traina F, Rocha V, Velloso E. Azevedo RS, et al. Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e1-e6. doi: 10.1016/j.clml.2021.07.026. Epub 2021 Jul 25. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34429274
BACKGROUND: Myelodysplastic Syndrome (MDS) with isolated deletion 5q is associated with a low risk to leukemic evolution and long overall survival (OS); it comprises 3%-4.5% of MDS cases in Latin America classified according to the World Health Organiz …
BACKGROUND: Myelodysplastic Syndrome (MDS) with isolated deletion 5q is associated with a low risk to leukemic e …
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS, List AF. Komrokji RS, et al. Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Ann Oncol. 2016. PMID: 26504152 Free PMC article. Review.
The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del( …
The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is a …
CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE, Kulasekararaj AG, Jiang J, Mian S, Mohamedali A, Gaken J, Ireland R, Czepulkowski B, Best S, Mufti GJ. Smith AE, et al. Lancet Haematol. 2015 May;2(5):e212-21. doi: 10.1016/S2352-3026(15)00050-2. Epub 2015 May 6. Lancet Haematol. 2015. PMID: 26688096
We aimed to establish the frequency, nature, and clinical association of CSNK1A1 mutations in patients with myelodysplastic syndrome and associated myeloid neoplasms. METHODS: Between June 1, 2004, and May 31, 2014, in King's College (London, UK …
We aimed to establish the frequency, nature, and clinical association of CSNK1A1 mutations in patients with myelodysplastic …
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ. Giagounidis A, et al. Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10. Ann Hematol. 2014. PMID: 24018623 Free PMC article. Review.
Deletion of the long arm of chromosome 5, del(5q), is the most prevalent cytogenetic abnormality in patients with myelodysplastic syndromes (MDS). In isolation, it is traditionally associated with favorable prognosis compared with other s …
Deletion of the long arm of chromosome 5, del(5q), is the most prevalent cytogenetic abnormality in patients with myelodysp …
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Syed YY, Scott LJ. Syed YY, et al. Drugs. 2013 Jul;73(11):1183-96. doi: 10.1007/s40265-013-0071-x. Drugs. 2013. PMID: 23824699 Review.
It is approved for the treatment of patients with transfusion-dependent anaemia due to International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome (MDS) associated with either chromosome 5q deletion [del(5q)] wit …
It is approved for the treatment of patients with transfusion-dependent anaemia due to International Prognostic Scoring System low- or inter …
Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.
Nolte F, Mossner M, Jann JC, Nowak D, Boch T, Müller NZ, Hofmann WK, Metzgeroth G. Nolte F, et al. Eur J Haematol. 2017 Mar;98(3):302-310. doi: 10.1111/ejh.12827. Epub 2016 Dec 27. Eur J Haematol. 2017. PMID: 27862375 Review.
Patients with monoclonal gammopathy of undetermined significance (MGUS) have a higher risk for the development of concomitant primary cancers such as multiple myeloma (MM) and myelodysplastic syndrome (MDS). We report the case of patient initially suffering from MGU …
Patients with monoclonal gammopathy of undetermined significance (MGUS) have a higher risk for the development of concomitant primary cancer …
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F. Mallo M, et al. Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23614682 Free article.
Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. ...In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 le …
Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), alth …
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge.
Sanders DS, Fennell T, Chisti MM. Sanders DS, et al. BMJ Case Rep. 2019 Apr 20;12(4):e227768. doi: 10.1136/bcr-2018-227768. BMJ Case Rep. 2019. PMID: 31005862 Free PMC article.
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy to assess haematological response after 6 months of initial lenalidomide therapy. ...While the exact clonal origin of both chromosomal a …
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow bio …
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Belickova M, Cermak J, Dostalova Merkerova M, Vesela J, Krejcik Z, Cechova E, Zemanova Z, Michalova K, Votavova H, Caniga M, Neuwirtova R, Jonasova A. Belickova M, et al. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):375-83. doi: 10.1016/j.clml.2012.04.003. Epub 2012 May 18. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22608605
We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from 6 patients with del(5q). Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway …
We used microarray profiling to investigate the direct effects of lenalidomide on gene expression in isolated CD14(+) monocytes from …
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres. Arcioni F, et al. Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22. Eur J Haematol. 2018. PMID: 29569278 Clinical Trial.
OBJECTIVE: The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isolated, is associated with refractory anaemia and good prognosis. ...CONCLUSIONS: Erythroid response to Lenalidomide was similar in …
OBJECTIVE: The most typical cytogenetic aberration in myelodysplastic syndromes is del(5q), which, when isola …
20 results